Wednesday, April 16, 2014

Aurinia to begin lupus nephritis trial in Q2

Aurinia to begin lupus nephritis trial in Q2

April 15, 2014 by · Leave a Comment 

Tweet Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient in the next few weeks in a Phase 2b clinical trial with its voclosporin immunosuppressant in combination with CellCept®, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “We are now well […]

Gour Medical in talks to expand animal health portfolio

Gour Medical in talks to expand animal health portfolio

April 8, 2014 by · Leave a Comment 

Tweet Upstart Gour Medical Animal Health, which recently agreed to acquire a portfolio of four products to be reformulated for pet care, is also negotiating for three or four additional products. “We are leveraging other people’s investments in the human biopharmaceutical industry to in-license products, improve their formulations and enhance their safety and efficacy, in […]

In conversation with Tony Pullen

In conversation with Tony Pullen

April 1, 2014 by · Leave a Comment 

Tweet Tony Pullen is one of the deans of Canadian capital markets. His career in biotech traces its roots to 1985 as an advisor to Cangene, which merged with Emergent BioSolutions (NYSE:EBS) in February. He also was instrumental in raising the initial capital for MDS Health Ventures, which went on to become MDS Capital Corp., […]

MRI Interventions’ ClearPoint changing brain surgery paradigm

MRI Interventions’ ClearPoint changing brain surgery paradigm

March 25, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=i5uavLiplP8′]

Tweet “Our goal is to transform the way brain surgery is performed to advance better treatment options for patients for whom current therapies are deficient.” So says Kimble Jenkins, CEO of MRI Interventions (OTCQB:MRIC), referring to the company’s ClearPoint surgical platform that provides real-time visualization via magnetic resonance image (MRI) guidance for a range of minimally […]

Transition moves into late-stage drug development

Transition moves into late-stage drug development

March 18, 2014 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has added late-stage drug development to its operations with its acquisition from Perrigo plc (NYSE, TASE:PRGO) of neuropsychiatric drug candidate, ELND005. “We’re maybe a year away from seeing the results of ELND005 in two Phase 2 trials for the treatment of agitation/aggression in patients with mild-to-severe Alzheimer’s disease (AD), and as an […]

Alpha Cancer to test oncology game changer

Alpha Cancer to test oncology game changer

March 11, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=HJr8cGE2eVs’]

Tweet Closely held Alpha Cancer Technologies, which is going public in a reverse takeover of Bradmer Pharmaceuticals (TSX-V:BMR-H), plans to begin testing patients with ovarian cancer this year with its drug candidate, ACT-901, which features a novel targeted drug delivery platform. BioTuesdays.com had an opportunity to interview the company’s founder & CEO, Dr. Igor Sherman, […]

Gamida Cell shifts focus to NiCord stem cell product

Gamida Cell shifts focus to NiCord stem cell product

March 4, 2014 by · Leave a Comment 

Tweet Closely held Gamida Cell has shifted its focus to its second-generation stem cell product, NiCord, for the treatment of hematological malignancies and non-malignant hematological diseases in the wake of an FDA decision last year for another pivotal trial of its first stem cell product, StemEx. “We view the clinical outcomes with NiCord as a […]

Advaxis readies cervical cancer pivotal trial

Advaxis readies cervical cancer pivotal trial

February 25, 2014 by · Leave a Comment 

Tweet Advaxis (NASDAQ:ADXS) hopes to begin a registration trial before the end of the year with its next-generation immunotherapy, ADXS-HPV, for the treatment of invasive cervical cancer. “We are pleased with the encouraging results of our Phase 2 study, which supports a continuing path towards registration for our lead product candidate,” CEO Daniel O’Connor says […]

Cynapsus PD data: couldn’t have wished for anything better

Cynapsus PD data: couldn’t have wished for anything better

February 18, 2014 by · Leave a Comment 

Tweet “If I had asked for a gift, I couldn’t have wished for anything better,” says Anthony Giovinazzo, president and CEO of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH). He was referring to a recently completed healthy volunteer pilot crossover trial, CTH103, which compared Cynapsus’ APL-130277, a sublingual thin film strip formulation of apomorphine, with a commercially available […]

In conversation with Michael Vidne

In conversation with Michael Vidne

February 11, 2014 by · Leave a Comment 

Tweet As director of business development for closely held NovellusDx, Michael Vidne has an enviable position in one of the hottest areas of health care: personalized medicine. A former consultant in the West Coast Office of McKinsey & Co., Dr. Vidne obtained his PhD in applied mathematics from Columbia University in NYC, where he researched […]

Next Page »

Google+